Hofseth BioCare ASA

OB:HBC Stock Report

Market Cap: NOK 719.4m

Hofseth BioCare Management

Management criteria checks 4/4

Hofseth BioCare's CEO is Jon Odegard, appointed in Aug 2022, has a tenure of 3.08 years. total yearly compensation is NOK2.07M, comprised of 94.1% salary and 5.9% bonuses, including company stock and options. directly owns 0.75% of the company’s shares, worth NOK5.40M. The average tenure of the management team and the board of directors is 4.6 years and 3.4 years respectively.

Key information

Jon Odegard

Chief executive officer

NOK 2.1m

Total compensation

CEO salary percentage94.14%
CEO tenure3.1yrs
CEO ownership0.8%
Management average tenure4.6yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

Hofseth BioCare ASA's (OB:HBC) Price Is Right But Growth Is Lacking

Aug 21
Hofseth BioCare ASA's (OB:HBC) Price Is Right But Growth Is Lacking

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Jul 17
Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Slammed 28% Hofseth BioCare ASA (OB:HBC) Screens Well Here But There Might Be A Catch

Apr 26
Slammed 28% Hofseth BioCare ASA (OB:HBC) Screens Well Here But There Might Be A Catch

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Apr 08
Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Hofseth BioCare ASA (OB:HBC) Might Not Be As Mispriced As It Looks After Plunging 31%

Mar 12
Hofseth BioCare ASA (OB:HBC) Might Not Be As Mispriced As It Looks After Plunging 31%

Hofseth BioCare ASA's (OB:HBC) Shares Leap 36% Yet They're Still Not Telling The Full Story

Dec 18
Hofseth BioCare ASA's (OB:HBC) Shares Leap 36% Yet They're Still Not Telling The Full Story

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Dec 17
Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt

Apr 01
Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt

We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt

Dec 22
We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt

Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?

Apr 28
Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Oct 16
Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?

Feb 24
Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?

How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?

Jan 28
How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?

Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?

Dec 25
Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Nov 20
Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

CEO Compensation Analysis

How has Jon Odegard's remuneration changed compared to Hofseth BioCare's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-NOK 137m

Mar 31 2025n/an/a

-NOK 129m

Dec 31 2024NOK 2mNOK 2m

-NOK 125m

Sep 30 2024n/an/a

-NOK 133m

Jun 30 2024n/an/a

-NOK 121m

Mar 31 2024n/an/a

-NOK 98m

Dec 31 2023NOK 3mNOK 2m

-NOK 107m

Sep 30 2023n/an/a

-NOK 93m

Jun 30 2023n/an/a

-NOK 105m

Mar 31 2023n/an/a

-NOK 140m

Dec 31 2022NOK 3mNOK 1m

-NOK 137m

Sep 30 2022n/an/a

-NOK 136m

Jun 30 2022n/an/a

-NOK 139m

Mar 31 2022n/an/a

-NOK 135m

Dec 31 2021n/an/a

-NOK 126m

Sep 30 2021n/an/a

-NOK 120m

Jun 30 2021n/an/a

-NOK 115m

Mar 31 2021n/an/a

-NOK 111m

Dec 31 2020NOK 2mNOK 695k

-NOK 102m

Sep 30 2020n/an/a

-NOK 104m

Jun 30 2020n/an/a

-NOK 90m

Mar 31 2020n/an/a

-NOK 86m

Dec 31 2019NOK 2mNOK 660k

-NOK 89m

Sep 30 2019n/an/a

-NOK 79m

Jun 30 2019n/an/a

-NOK 81m

Mar 31 2019n/an/a

-NOK 83m

Dec 31 2018NOK 2mNOK 702k

-NOK 85m

Compensation vs Market: Jon's total compensation ($USD205.49K) is below average for companies of similar size in the Norwegian market ($USD363.47K).

Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.

CEO

Jon Odegard

3.1yrs
Tenure
NOK 2,065,000
Compensation

Mr. Jon Olav Odegard had been Chief Financial Officer of Hofseth BioCare ASA since August 29, 2016 until 2022 and serves as its Chief Executive Officer since August 1, 2022 and was its Chief Executive Offi...

Leadership Team

NamePositionTenureCompensationOwnership
Jon Odegard
Chief Executive Officer3.1yrsNOK 2.07m0.75%
NOK 5.4m
Bomi Framroze
Chief Scientific Officer15.7yrsNOK 9.09m1.26%
NOK 9.1m
James Berger
Chief Commercial Officer4.6yrsNOK 2.03mno data
Angelika Florvaag
Chief Quality Officer4.6yrsNOK 1.39mno data
Magnus Havnen
Head of Supply Chainno datano datano data
Tom James
Head of Manufacturingno datano datano data
Paul Bruhn
Head of New Business Developmentno datano datano data
4.6yrs
Average Tenure

Experienced Management: HBC's management team is considered experienced (4.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Crawford Linden Currie
Director3.7yrsNOK 96.00k0.18%
NOK 1.3m
Roger Hofseth
Director3.1yrsNOK 104.00k14.55%
NOK 104.6m
Maria Bech
Independent Director1.7yrsNOK 55.00kno data
Amy Novogratz
Independent Director3.8yrsno datano data
Christoph Baldegger
Independent Director10.7yrsNOK 106.00k0.79%
NOK 5.7m
Linda Hoff
Independent Chair of the Board1.7yrsNOK 91.00kno data
3.4yrs
Average Tenure
54yo
Average Age

Experienced Board: HBC's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/05 20:38
End of Day Share Price 2025/09/05 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hofseth BioCare ASA is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonas PeciulisNorne Securities AS
Henning SteffenrudSwedbank Norway